Genetic Breakthrough May Aid Parkinson's Misdiagnosis

Researchers identify key proteins linked to progressive supranuclear palsy, a rare neurodegenerative disease often mistaken for Parkinson's.

Mar. 14, 2026 at 12:16am

Got story updates? Submit your updates here. ›

Researchers have discovered a potential biomarker that could help distinguish progressive supranuclear palsy (PSP), a rare and aggressive neurodegenerative disease, from Parkinson's disease. PSP shares similar symptoms with Parkinson's, making it challenging to diagnose accurately. The study identified a protein called DLX1 that is enriched in the brains of people with PSP, suggesting it could be used to confirm a PSP diagnosis. Reducing DLX1 levels in fruit fly models also minimized the damage caused by the buildup of tau protein, a hallmark of PSP. These findings could lead to improved diagnostic tools and potential treatments for this devastating disease.

Why it matters

Progressive supranuclear palsy is often misdiagnosed as Parkinson's disease due to their overlapping symptoms, leading to ineffective treatments and a worsening of the patient's condition. This new research provides the first evidence linking key proteins to the development of PSP, which could enable earlier and more accurate diagnoses as well as the development of targeted therapies.

The details

The study found that a single mutation in the gene coding for the stress sensor protein PERK increases a person's risk of developing PSP. Unlike properly functioning PERK, the mutant form of this protein could not eliminate tau clumps in the brain, suggesting the brain normally has a way to get rid of toxic tau that is compromised in people with the mutation. The researchers then identified four proteins, including DLX1, that were affected by the mutant form of PERK. They found that reducing DLX1 levels in fruit fly models engineered to produce high levels of tau minimized the damage to brain cells.

  • The patient's father's first fall occurred on his 65th birthday.
  • The patient's father was diagnosed with Parkinson's disease but died within 10 years, having been misdiagnosed with the rare and aggressive progressive supranuclear palsy.
  • The late Rev. Jesse Jackson, who died on Feb. 17, 2026, at age 84, had a similar experience of being misdiagnosed with progressive supranuclear palsy.

The players

Jose Abisambra

A professor of neuroscience at the University of Florida who led the research team that identified a potential biomarker for progressive supranuclear palsy.

Jesse Jackson

A civil rights leader who was misdiagnosed with progressive supranuclear palsy before his death in 2026 at the age of 84.

PERK

A stress sensor protein that, in its mutant form, is unable to eliminate tau clumps in the brain, contributing to the development of progressive supranuclear palsy.

DLX1

A protein identified in the study that is enriched in the brains of people with progressive supranuclear palsy and may play a role in the development of the disease.

Got photos? Submit your photos here. ›

What they’re saying

“Yes, doctor. My dad's first fall was on his 65th birthday. He stood in the driveway and suddenly dropped backwards on his back. After he fell two more times, we came to the clinic.”

— Jose Abisambra, Professor of Neuroscience, University of Florida (Mirage News)

What’s next

Researchers are currently testing three other proteins identified in the study to see if they can also offer improved diagnostic and therapeutic value for progressive supranuclear palsy. Combination therapies targeting these proteins could potentially help improve patients' lives.

The takeaway

This study provides the first evidence linking key proteins to the development of progressive supranuclear palsy, a rare and devastating neurodegenerative disease that is often misdiagnosed as Parkinson's. These findings could lead to earlier and more accurate diagnoses, as well as the development of targeted treatments to improve the quality of life for patients suffering from this debilitating condition.